Phase I trial of cisplatin, WR-2721, and the murine monoclonal antibody R24 in patients with metastatic melanoma: clinical and biologic effects.
The therapeutic and biologic effects of murine monoclonal antibodies in patients with malignancies have been widely investigated. Attempts to enhance results by combining these agents with cytotoxic drugs are now under study. A Phase I trial was performed to assess the toxicity and biologic effects of escalating doses of R24 (0-40 mg/m2/day 1-5, 8-12), an antibody that binds to the ganglioside GD3 present on melanoma cells, administered in combination with cisplatin (120 mg/m2) and WR-2721 (740 mg/m2) on day 1. Twenty-three patients with metastatic malignant melanoma were treated and are evaluable. The true maximum tolerated dose of R24 given as part of this combination was not reached. The toxicity of the regimen was moderate and included fever and urticaria, which were attributed to R24. Severe but reversible renal failure was noted in six patients in subsequent (two or more) treatment cycles, but when cisplatin was administered in 3% saline, this toxicity was not seen. Responses were seen in 2 of 19 patients receiving all three agents and in 1 of 4 patients receiving only cisplatin and WR-2721. No significant enhancement of natural killer, lymphokine-activated killer, and antibody-dependent cellular cytotoxicity lytic activity or significant changes from baseline in lymphocyte subsets secondary to R24 were seen. In 4 of 10 patients tumor localization of mouse monoclonal antibody was found and appeared greatest at higher R24 doses and during week 1 of therapy. Human anti-mouse antibody responses developed by day 22 in 17 of 19 patients treated with R24, and the coadministration of cisplatin did not appear to abrogate this response. Finally, the half-life and Cmax of cisplatin were not affected by R24. In summary, the combination was well tolerated, responses were few, and significant biologic interactions or immunomodulation were not observed.
Bukowski
R M
RM
Experimental Therapeutics Program, Cleveland Clinic Cancer Center, Ohio.
Murthy
S A
SA
Finke
J
J
Caulfield
M J
MJ
Tubbs
R
R
Herzog
P
P
Stanley
J
J
Edinger
M
M
Tuason
L
L
McLain
D
D
D000328:Adult; D000368:Aged; D004999:Amifostine / Q000627:therapeutic use*; D000818:Animals; D000910:Antibodies, Heterophile / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D002945:Cisplatin / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003601:Cytotoxicity Tests, Immunologic; D005434:Flow Cytometry; D006801:Humans; D008545:Melanoma / Q000556:secondary* / Q000628:therapy*; D051379:Mice; D008875:Middle Aged
D000910:Antibodies, Heterophile; D000911:Antibodies, Monoclonal; D004999:Amifostine; D002945:Cisplatin